Terry-Ann Burrell served as the chief financial officer at Beam Therapeutics, a biotechnology company focused on developing precision genetic medicines.
Terry-Ann Burrell served as the chief financial officer at Beam Therapeutics, a biotechnology company focused on developing precision genetic medicines through base editing. During her five-year tenure, she played a crucial role in the company's IPO, built out its finance and corporate affairs functions, and helped raise significant capital. She is leaving Beam Therapeutics on August 9, 2024, to become vice chairman of investment banking at JPMorgan Chase.
Full founder directory · Investor directory · Company funding database · Fundraising library